How should a glucagon challenge be performed and interpreted in a patient with documented hypoglycemia?

Glucagon Challenge in Hypoglycemia

Administer 1.0 mg of glucagon intravenously at the end of a documented hypoglycemic episode (plasma glucose <55 mg/dL), then measure plasma glucose at 10,20, and 30 minutes post-injection; a rise of ≥25 mg/dL indicates insulin-mediated hypoglycemia, while a blunted response (<25 mg/dL rise) suggests hepatic glycogen depletion or non-insulin-mediated mechanisms. 1

When to Perform the Glucagon Challenge

The glucagon stimulation test should be performed in two specific contexts according to the 2009 Endocrine Society Clinical Practice Guidelines:

During spontaneous hypoglycemia:

• When plasma glucose is documented <55 mg/dL (3.0 mmol/L) with symptoms 1
• Collect baseline samples for glucose, insulin, C-peptide, proinsulin, and β-hydroxybutyrate before glucagon administration

At the end of a supervised fast:

• After completing a 72-hour fast when plasma glucose falls to <45 mg/dL with symptoms (or <55 mg/dL if Whipple's triad was previously documented) 1
• Immediately before administering treatment for the hypoglycemia

How to Perform the Test

Administration protocol 1:

• Inject 1.0 mg glucagon intravenously (preferred in diagnostic setting)
• Alternatively, can give intramuscularly if IV access unavailable
• Measure plasma glucose at baseline, then at 10,20, and 30 minutes post-injection
• Use laboratory-measured plasma glucose, not point-of-care monitors, for diagnostic decisions

Critical samples to collect before glucagon 1:

• Plasma glucose
• Insulin
• C-peptide
• Proinsulin
• β-hydroxybutyrate
• Screen for oral hypoglycemic agents
• Insulin antibodies (can be measured later, not necessarily during hypoglycemia)

Interpretation of Results

Insulin-mediated hypoglycemia (insulinoma or exogenous insulin) 1:

• Glucose rise ≥25 mg/dL (1.4 mmol/L) after glucagon
• β-hydroxybutyrate ≤2.7 mmol/L at baseline
• Elevated insulin (≥3.0 µU/mL) and C-peptide (≥0.6 ng/mL) at baseline
• This response indicates adequate hepatic glycogen stores that can be mobilized

Non-insulin-mediated hypoglycemia 2:

• Glucose rise <25 mg/dL (1.4 mmol/L) after glucagon
• β-hydroxybutyrate >2.7 mmol/L at baseline (indicating ketogenesis)
• Low insulin (<3.0 µU/mL) and C-peptide (<0.6 ng/mL) at baseline
• Suggests hepatic glycogen depletion, liver failure, or non-islet cell tumor hypoglycemia

Distinguishing insulinoma from other causes 3:

• Insulinoma patients may show paradoxical insulin secretion in response to glucagon even during hypoglycemia
• Measure insulin and C-peptide levels after glucagon administration—rising levels despite low glucose strongly suggest insulinoma
• This is particularly useful when fasting tests are equivocal

Clinical Nuances and Pitfalls

Important caveats:

1. Hepatic metastases complicate interpretation 4, 5: Patients with liver metastases from hepatocellular carcinoma or other tumors may have impaired glucagon responses due to depleted glycogen stores, mimicking non-insulin-mediated hypoglycemia even when insulin-like growth factors are involved

2. False negatives can occur 3: A case report documented an insulinoma patient with normal 72-hour fasts who only demonstrated diagnostic findings after glucagon administration triggered exaggerated insulin secretion and subsequent hypoglycemia

3. Timing matters: The glucagon challenge is most informative when performed during documented biochemical hypoglycemia, not in the euglycemic state

4. Mixed responses exist 4: Some patients with non-islet cell tumor hypoglycemia show adequate glucagon responses if glycogen stores are preserved, while others with the same diagnosis show blunted responses if liver function is compromised

Algorithmic Approach

Step 1: Document Whipple's triad (symptoms + glucose <55 mg/dL + relief with glucose)

Step 2: During hypoglycemia, collect critical samples (glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate, sulfonylurea screen)

Step 3: Administer 1.0 mg glucagon IV

Step 4: Measure glucose at 10,20,30 minutes

Step 5: Interpret results:

• If glucose rises ≥25 mg/dL + elevated baseline insulin/C-peptide → Endogenous hyperinsulinism (proceed to insulinoma localization)
• If glucose rises ≥25 mg/dL + low baseline insulin/C-peptide → Exogenous insulin or insulin antibodies (check sulfonylurea screen and insulin antibodies)
• If glucose rises <25 mg/dL + low baseline insulin/C-peptide → Non-insulin-mediated (evaluate for liver disease, hormone deficiencies, non-islet cell tumors)

Step 6: Consider measuring post-glucagon insulin/C-peptide levels if insulinoma suspected but baseline values equivocal 3

The glucagon challenge remains a cornerstone diagnostic test that rapidly distinguishes insulin-mediated from non-insulin-mediated hypoglycemia, guiding both immediate management and long-term therapeutic strategies 1, 2.